PMWC 2014 ISRAEL LUMINARY AWARD, Developer, First Predictive Test for Huntington’s Disease
M.D., Ph.D., President, Global R&D and Chief Scientific Officer, Teva
Dr. Hayden has international standing as a research scientist and clinician. He has an outstanding record of leadership, innovation, and is a clinician-scientist who has spent his entire working life in research that has led directly to medicines which have made a substantial difference to patients around the world. His work in genetics and personalized medicine is internationally renowned, and he is one of the world’s leading experts on Huntington’s disease.
Dr. Hayden also has extensive experience in all stages of medicine development – from target identification, through the complete cycle of clinical development, to submission and approval processes with regulators around the world.
Currently, he is Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
Dr. Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Pharmaceuticals Inc. In 2011, he was awarded the Canada Gairdner Wightman award, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. In 2010, he was awarded the Order of Canada, which is the highest honor that Canada can give its citizens for exceptional achievement, merit or service.
In 2008 he was named Canada's Health Researcher of the Year and in 1998 received the Distinguished Scientist Award of the Canadian Society of Clinical Investigation. These are just some of the array of major honors and awards that demonstrate the esteem in which he is held internationally.